HIV/AIDS Kaposis Sarcoma: Comparison of Response to HAART vs HAART Plus CXT (KAART)

This study has been completed.
Sponsor:
Collaborators:
AIDS Care Research in Africa
National Research Foundation, Singapore
AIDS Malignancy Consortium
Cipla Medpro
Dermatological Society of South Africa
Information provided by:
University of KwaZulu
ClinicalTrials.gov Identifier:
NCT00380770
First received: September 25, 2006
Last updated: July 20, 2010
Last verified: March 2009
  Purpose

Kaposi's sarcoma (KS)is the commonest malignancy associated with HIV/AIDS. Therapy for this cancer, which causes substantial morbidity, is suboptimal in resource poor settings. The reasons for this are: advanced state of immunosuppression when patients present for clinical care, concomitant opportunistic infections, non- availability of antiretroviral therapy (ART), non-availability and toxicity of chemotherapy (CXT), when available, in patients with full blown AIDS, prohibitive costs of bone marrow support and fiscal constraints in resource poor settings.

A recent Cochrane Review assessed the effectiveness of current therapeutic regimens for HIV KS, with a focus on options available in resource poor settings. The major selection criteria for this review were randomized controlled trials for HIV KS in adults. The main conclusions were that data from randomized controlled trials on effective treatments for HIV KS are sparse, particularly among people who are also taking highly active antiretroviral therapy (HAART). Alitretinoin gel is effective for therapy of cutaneous lesions, pegylated liposomal doxorubicin is effective for advanced KS and radiotherapy is effective for treating cutaneous lesions. Apart from the randomized trial of radiotherapy, no trials applicable to developing settings were identified. Therapy of HIV KS in developing countries thus remains unanswered.

The authors concluded that therapies discussed in the review are unlikely to be available or affordable in developing countries where the bulk of HIV infection and KS occur, apart from radiotherapy at a few tertiary centers. However, recent changes in pricing due to the global alliance and access initiatives mean that HAART is likely to be more available and accessible to developing countries in the near future. South Africa now has committed to this at cabinet level and had a task force to address this issue.

HAART has been proposed as therapy for HIV KS on the basis of restoring immune competence and minimizing the HIV tat drive to KS formation. It also improves immunologic control of HHV 8 possibly through interrupting the HIV-1- HHV-8 interaction.

There has been only one randomised trial conducted in Spain which compared HAART to the combination of HAART and CXT. There is to date no prospective, randomised controlled trial which compares the efficacy of HAART to the standard of care in HIV KS in Africa.


Condition Intervention Phase
HIV
AIDS
Kaposi's Sarcoma
Human Herpesvirus 8
Drug: Generic HAART Triomune : d4T, 3TC, NVP
Drug: Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Prospective Randomized Trial Comparing the Response of HIV Kaposi's Sarcoma (KS) to HAART Versus the Combination of HAART and Chemotherapy (CXT)

Resource links provided by NLM:


Further study details as provided by University of KwaZulu:

Primary Outcome Measures:
  • Clinical response of KS [ Time Frame: 3 monthly ] [ Designated as safety issue: No ]
    Responses will be categorized as complete response(only with biopsy confirmation), complete clinical response, partial response, stable disease and disease progression according to ACTG criteria.

  • Skin: tumour measurements of 5 indicator skin lesions. Assessment of KS as per AMC RKS 02 (www.amc.uab.edu) [ Time Frame: 3 monthly ] [ Designated as safety issue: No ]
    Measurement of the same 5 marker lesions (as per AMC RKS 02 )will be done at baseline, month 3, month 6, month 9 and month 12. Assessed by bi-directional diameter.

  • photography of indicator lesions with metric tape in frame [ Time Frame: 6 monthly ] [ Designated as safety issue: No ]
    Clinical photographs taken of marker lesions (5 according to AMC criteria) will be taken at baseline, month 6 and 12.

  • Visceral: chest radiograph and endoscopy, where necessary, bronchoscopy [ Time Frame: 6 monthly ] [ Designated as safety issue: No ]
    done in patients who presented with visceral KS at baseline to monitor the disease


Secondary Outcome Measures:
  • Safety and toxicity by DAIDS Toxicity criteria [ Time Frame: as they occur ] [ Designated as safety issue: Yes ]
    DAAIDS toxicity criteria used to assess and measure severity of adverse events

  • Immunological and virological response to HAART as measured by CD4 and HIV-viral load [ Time Frame: 3 monthly ] [ Designated as safety issue: No ]
    patients CD4 and VL will be measured 3 monthly to assess immunological and virological control

  • QOL by EORTC QLQ C30 [ Time Frame: 3 monthly ] [ Designated as safety issue: No ]
    EORTC QLQ C30 will be used as the tool to assess QOL in subjects

  • Adherence [ Time Frame: monthly ] [ Designated as safety issue: No ]
    Adherence by 7 day adherence questionnaire Adherence will be measured using a standardized validated self administered questionnaire, which enables review of each medication during previous 7 days and a medication specific and overall adherence score.


Enrollment: 112
Study Start Date: January 2003
Study Completion Date: March 2009
Primary Completion Date: February 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: HAART alone
Arm 1. HAART These patients will be given one tablet twice daily of Triomune® (Cipla, Mumbai) Stavudine 40mg b.d > 60 kg , 30mg bd <60kg Lamivudine 150mg b.d > 50 kg 2mg/kg < 50 kg Nevirapine 200mg b.d ( 200mg daily for first 2 weeks)
Drug: Generic HAART Triomune : d4T, 3TC, NVP
Triomune® (Cipla, Mumbai) Stavudine 40mg b.d > 60 kg , 30mg bd <60kg Lamivudine 150mg b.d > 50 kg 2mg/kg < 50 kg Nevirapine 200mg b.d ( 200mg daily for first 2 weeks)
Active Comparator: Combination HAART and chemotherapy
Arm 2. CTX PLUS HAART. HAART will be given as above. In addition, CTX will be administered at 2 weekly intervals in the Oncology Dept at KEH VIII Hospital and will consist of:- Intramuscular Bleomycin 10 U/m2 ; Intravenous Vincristine 1.4mg/m2 maximum 2mg and Intravenous Doxorubicin 20mg/m2.
Drug: Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV
Triomune® (Cipla, Mumbai) Stavudine 40mg b.d > 60 kg , 30mg bd <60kg Lamivudine 150mg b.d > 50 kg 2mg/kg < 50 kg Nevirapine 200mg b.d ( 200mg daily for first 2 weeks) Intramuscular Bleomycin 10 U/m2 ; Intravenous Vincristine 1.4mg/m2 maximum 2mg and Intravenous Doxorubicin 20mg/m2.

  Hide Detailed Description

Detailed Description:

DETAILED METHODOLOGY

PRIMARY OBJECTIVES:

1.To compare the clinical response of HIV KS at month 12 in patients treated with HAART alone with those treated with the combination of HAART and chemotherapy (CXT).

SECONDARY OBJECTIVES

  1. To monitor safety, tolerance and adverse events associated with each regimen.
  2. To compare the impact of each regimen at baseline and months 12 on:

    1. CD4 count
    2. HIV1 viral load in blood
    3. HIV disease progression
  3. To compare the impact of each regimen on the patients Quality of life (QOL).
  4. To compare the impact of each regimen on the patients adherence to HAART. 5 To measure and compare HHV8 viral load and HHV8 specific CTL responses at baseline and month 12 to each regimen.(in blood and tissue specimens )

DESIGN Prospective, randomized, open- labeled trial

RANDOMISATION Patients first staged into GOOD risk and POOR risk groups according to ACTG criteria. Thereafter 4 digit computer generated numbers after staging which assign patients to HAART alone or HAART plus CXT to ensure that equal numbers of GOOD and POOR risk patients are assigned to each group.

INCLUSION CRITERIA

  • Signed informed consent
  • Adults > 18 years
  • Documented HIV positive status (Confirmed by two ELISAs and HIV-1 RNA testing)
  • Willingness to use a barrier method of birth control throughout the course of the study, because of potential drug interactions that make oral contraceptives less effective (for women of childbearing potential) and sexually active males
  • Histologically proven
  • At least five measurable, previously unirradiated cutaneous lesions must be present which can be used as indicator lesions.
  • ECOG performance status 0-2

EXCLUSION CRITERIA

  • Pregnancy or breastfeeding
  • Fungating tumors of KS
  • Symptomatic pulmonary KS
  • Symptomatic GI tract KS
  • Clinical evidence of peripheral neuropathy
  • Clinical evidence of heart disease
  • Total neutrophil count of < 1,000u/L, Hemoglobin < 9.0gm/dl or platelet count of < 75,000u/L; serum creatinine > 1.5mgh/dl, direct serum bilirubin > 85 umol/l, AST or ALT > 2.5 time ULN.
  • Prior HAART ( to fairly evaluate antiretroviral response and KS response to HAART, patients should be antiretroviral naïve)
  • Prior radiation therapy for KS to sites of indicator lesions.
  • Prior cytotoxic chemotherapy for KS.
  • Concurrent neoplasia requiring cytotoxic therapy.
  • Life expectancy of < 3 months.
  • Circumstances, which in the opinion of the investigator make it unlikely the patient, can comply with the safety monitoring required for participation in this trial.

INTERVENTION Arm 1. HAART These patients will be given one tablet twice daily of Triomune® (Cipla, Mumbai) Stavudine 40mg b.d > 60 kg , 30mg bd <60kg Lamivudine 150mg b.d > 50 kg 2mg/kg < 50 kg Nevirapine 200mg b.d ( 200mg daily for first 2 weeks)

Arm 2. CTX PLUS HAART HAART will be given as above. In addition, CTX will be administered at 2 weekly intervals in the Oncology Dept at KEH VIII Hospital and will consist of:- Intramuscular Bleomycin 10 U/m2 ; Intravenous Vincristine 1.4mg/m2 maximum 2mg and Intravenous Doxorubicin 20mg/m2.

This regimen will be given at 2 weekly intervals. This will be supplied by the Department of Oncology, KwaZulu Natal Province.

PRIMARY ENDPOINTS

  1. Clinical response of KS

    • Clinical photographs taken of marker lesions (5 according to AMC criteria) will be taken at baseline, month 6 and 12.
    • Lesion measurement of 5 marker lesions (as per AMC RKS 02 )(www.amc.uab.edu) will be done at baseline, month 3, month 6, month 9 and month 12. Responses will be categorized as complete response(only with biopsy confirmation), complete clinical response, partial response, stable disease and disease progression according to ACTG criteria.
    • The patients will be assessed by a specialist dermatologist, trained to use the above instruments, and will be the same individual so as to decrease bias introduced with inter-observer variability. We recognize that there is the potential for bias as the study is not blinded and dermatologist will know patient assignment. For that reason, we are using established objective criteria to evaluate response.
    • Biopsies will be performed at baseline, month 6 and month 12 to assist in confirming response and to evaluate HIV and HHV8 tissue viral loads
  2. Safety and toxicity by DAIDS Toxicity criteria
  3. QOL by EORTC QLQ C30
  4. Adherence by 7 day adherence questionnaire Adherence will be measured using a standardized validated self administered questionnaire, which enables review of each medication during previous 7 days and a medication specific and overall adherence score.
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Signed informed consent
  • Adults > 18 years
  • Documented HIV positive status (Confirmed by two ELISAs and HIV-1 RNA testing)
  • Willingness to use a barrier method of birth control throughout the course of the study, because of potential drug interactions that make oral contraceptives less effective (for women of childbearing potential) and sexually active males
  • Histologically proven
  • At least five measurable, previously unirradiated cutaneous lesions must be present which can be used as indicator lesions.
  • ECOG performance status 0-2

Exclusion Criteria:

  • • Pregnancy or breastfeeding

    • Fungating tumors of KS
    • Symptomatic pulmonary KS
    • Symptomatic GI tract KS
    • Clinical evidence of peripheral neuropathy
    • Clinical evidence of heart disease
    • Total neutrophil count of < 1,000u/L, Hemoglobin < 9.0gm/dl or platelet count of < 75,000u/L; serum creatinine > 1.5mgh/dl, direct serum bilirubin > 85 umol/l, AST or ALT > 2.5 time ULN.
    • Prior HAART ( to fairly evaluate antiretroviral response and KS response to HAART, patients should be antiretroviral naïve)
    • Prior radiation therapy for KS to sites of indicator lesions.
    • Prior cytotoxic chemotherapy for KS.
    • Concurrent neoplasia requiring cytotoxic therapy.
    • Life expectancy of < 3 months.
    • Circumstances, which in the opinion of the investigator make it unlikely the patient, can comply with the safety monitoring required for participation in this trial.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00380770

Locations
South Africa
Department of Dermatology, King Edward VIII Hospital
Durban, Kwazulu Natal, South Africa, 4001
Sponsors and Collaborators
University of KwaZulu
AIDS Care Research in Africa
National Research Foundation, Singapore
AIDS Malignancy Consortium
Cipla Medpro
Dermatological Society of South Africa
Investigators
Principal Investigator: Anisa Mosam, FC Derm,PhD Nelson R Mandela School of Medicine, University of Kwazulu Natal
  More Information

Publications:
Responsible Party: Dr Anisa Mosam, Department of Dermatology UKZN
ClinicalTrials.gov Identifier: NCT00380770     History of Changes
Other Study ID Numbers: H029/02
Study First Received: September 25, 2006
Last Updated: July 20, 2010
Health Authority: South Africa: Medicines Control Council

Keywords provided by University of KwaZulu:
HIV
AIDS
Kaposi's sarcoma
Human herpesvirus 8

Additional relevant MeSH terms:
Sarcoma
Sarcoma, Kaposi
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms
Herpesviridae Infections
DNA Virus Infections
Virus Diseases
Neoplasms, Vascular Tissue
Stavudine
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Therapeutic Uses
Anti-HIV Agents

ClinicalTrials.gov processed this record on October 01, 2014